On September 12, 2014, a robotics start-up called ReWalk went public.
By the end of the day, Crowdability readers like you who’d invested in ReWalk when it was still private were sitting on estimated gains of 536%.
But I’m not telling you this to make you jealous…
I’m telling you because you’ve got a shot at similar gains today.
ReWalk Robotics (Nasdaq: RWLK) makes a bionic assisted walking system.
Simply put, it allows paraplegics to walk again.
About fifteen months before its IPO, ReWalk used a crowdfunding platform to raise money from investors like you.
And when ReWalk went public, those investors were able to sell their shares while everyone else was buying.
In other words, they cashed out while everyone else was jumping in.
And here’s the thing:
A similar trade might be taking shape right now.
Myomo is a medical robotics company.
In many ways, it’s similar to ReWalk.
But whereas ReWalk focuses on solutions for lower extremity paralysis, Myomo focuses on solutions for upper extremity paralysis.
Here’s what its device looks like:
The way it works is somewhat magical:
First, its patented technology continuously monitors the affected muscles.
Then, when the device senses the user’s intent to move the arm (it senses this intent via electromyography, or EMG), it enables the desired motion.
Best of all, for the patient, this processing occurs quickly and effortlessly.
Myomo’s technology was developed at MIT and Harvard Medical School.
Ten years ago, it was spun out as a commercial enterprise.
Since then, it’s raised about $20 million to get its device into hospitals like the Mayo Clinic. And it’s done more than $1 million in sales, with gross margins of 70%.
And now, given the company’s success—and given the $30 billion global market potential for its devices—Myomo is raising up to $50 million for expansion.
Which is where you come in…
Mini-IPO on Deck
To raise this round of capital, Myomo is leveraging a provision of the JOBS Act called “Regulation A+,” or as it’s more commonly known, “The Mini-IPO.”
This funding strategy allows the company to raise money from all individuals, regardless of their income or net worth.
The fundraise will take place on a crowdfunding platform called Banq.
If the fundraise is successful, Myomo intends to take the company public on the New York Stock Exchange (NYSE) using the ticker “MYO.”
Learn More Here
To be clear, I’m not recommending you run out and invest in Myomo.
After all, this is a risky venture that requires substantial investment research.
And furthermore, we only make formal recommendations in our premium research services.
But if Myomo piques your interest, it might be worth taking a deeper look:
First of all, it’s aiming to be the global solution to upper extremity paralysis. If it succeeds, it could become a large business that does a lot of good.
Secondly, because the company is currently in a stage of its Mini-IPO process called “Testing the Waters,” you can indicate your interest in making an investment now—but you can back out later with no penalties.
And lastly, we can’t help but see similarities between Myomo and ReWalk…
And if Myomo’s private investors make the same kind of gains we saw with ReWalk, that would put a smile on our face.
To see a video of Myomo’s device in action, click here »
And to learn more about Myomo fundraise on Banq, click here »
Please note: Crowdability has no relationship with Myomo or Banq, or with any of the companies or platforms we write about. Crowdability is an independent provider of education, information and research on start-ups and alternative investments.